BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23691506)

  • 1. Development of an ammonium sulfate DNA extraction method for obtaining amplifiable DNA in a small number of cells and its application to clinical specimens.
    Oh SY; Kim WY; Hwang TS; Han HS; Lim SD; Kim WS
    Biomed Res Int; 2013; 2013():546727. PubMed ID: 23691506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
    Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
    Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas.
    Kang SY; Ahn S; Lee SM; Jeong JY; Sung JY; Oh YL; Kim KM
    Diagn Pathol; 2013 Jul; 8():121. PubMed ID: 23883275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary thyroid carcinoma.
    Kim TE; Jung ES; Jung CK; Bae JS; Kim SN; Kim GS; Lee HN; Kang CS; Choi YJ
    Exp Mol Pathol; 2013 Feb; 94(1):203-9. PubMed ID: 22691412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.
    Smith GD; Zhou L; Rowe LR; Jarboe EA; Collins BT; Bentz JS; Wittwer CT; Chadwick BE
    Acta Cytol; 2011; 55(6):576-83. PubMed ID: 22156469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a DNA Extraction and Purification Protocol Using Archived Formalin-fixed Paraffin-embedded Tissues for BRAF Mutations Analysis in Papillary Thyroid Microcarcinomas.
    Nechifor-Boilă A; Loghin A; Descotes F; Decaussin-Petrucci M; Borda A
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):70-76. PubMed ID: 28549037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of BRAF V600E mutation in thyroid fine-needle aspiration specimens by High Resolution Melting (HRM) analysis.
    Nechifor-Boilă A; Decaussin-Petrucci M; Gazzo S; Paşcanu I; Borda A
    Rom J Morphol Embryol; 2012; 53(2):263-7. PubMed ID: 22732794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of BRAF mutations on direct smears of thyroid fine-needle aspirates through cell transfer technique.
    Shi Q; Ibrahim A; Herbert K; Carvin M; Randolph M; Post KM; Curless K; Chen S; Cramer HM; Cheng L; Wu HH
    Am J Clin Pathol; 2015 Apr; 143(4):500-4. PubMed ID: 25780001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens.
    Gallegos Ruiz MI; Floor K; Rijmen F; Grünberg K; Rodriguez JA; Giaccone G
    Cell Oncol; 2007; 29(3):257-64. PubMed ID: 17452778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis.
    Rowe LR; Bentz BG; Bentz JS
    J Clin Pathol; 2007 Nov; 60(11):1211-5. PubMed ID: 17298986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
    Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
    Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The suitability of DNA extracted from formalin-fixed, paraffin-embedded tissues for double differential polymerase chain reaction analysis.
    Bielawski K; Zaczek A; Lisowska U; Dybikowska A; Kowalska A; Falkiewicz B
    Int J Mol Med; 2001 Nov; 8(5):573-8. PubMed ID: 11605030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing.
    Yeo MK; Jung MK; Lee SY; Lee YM; Hur GM; Kim JM
    J Clin Pathol; 2017 Mar; 70(3):260-265. PubMed ID: 27543599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
    da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
    Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.